Hoth Therapeutics, Inc. announced t that it has received written approval from the University of Texas MD Anderson Cancer Center Institutional Review Board (IRB) to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi. More information can be found at clinicaltrials.gov.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.164 USD | -2.96% | -2.14% | -19.13% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.13% | 5.87M | |
+39.59% | 723B | |
+34.28% | 595B | |
-4.04% | 369B | |
+20.29% | 332B | |
+2.85% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.35% | 168B |
- Stock Market
- Equities
- HOTH Stock
- News Hoth Therapeutics, Inc.
- Hoth Therapeutics Announces Irb Approval for Fda Cleared First-In-Human Clinical Trial of Ht-001 At Second Clinical Site